Birgit Bremer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Birgit Bremer has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Heiner Wedemeyer
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
5 shared publications - Markus Cornberg
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
3 shared publications - Anke Renate Maria Kraft
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
2 shared publications - Benjamin Maasoumy
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology Hannover Medical School Hannover Germany
2 shared publications Katja Deterding
2 shared publications- Michael Peter Manns
European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
2 shared publications
Latest Publications
- Open Access
- 18 October 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (1)
Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis D
- 18 October 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (1)
Open AccessTreatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis D
- 19 December 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 82 (3) , 739-754
Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition
Background and Aims: Chronic HBV infection exhausts HBV-specific T cells, develops epigenetic imprints that impair immune responses, and limits the effectiveness of immune checkpoint inhibitor monotherapy, such as anti–programmed cell death ligand-1 antibody (αPD-L1). This study aimed to determine whether the DNA methyltransferase inhibitor decitabine (DAC) could reverse these epigenetic imprints and enhance immune checkpoint inhibitor efficacy in restoring HBV-specific T cell responses. Approach and Results: We investigated HBV-specific T cell responses by 10-day in vitro stimulation of peripheral blood mononuclear cells (PBMCs) from patients with chronic HBV infection. PBMCs were stimulated with HBV core-specific overlapping peptide pools and HLA-A*02–restricted peptides, core18 and pol455. The immunomodulatory effect of the DAC/αPD-L1 combination was assessed by flow cytometry, and our analysis included clinical characteristics, ex vivo DNA methylation of PBMCs, and IFNγ plasma levels. Treatment with DAC/αPD-L1 enhanced HBV-specific CD4+ T cell responses in a significant proportion of 53 patients, albeit with some variability. This effect was independent of the HBcrAg levels. Ex vivo DNA methylation revealed hypermethylation of key genes, such as IFNG among DAC-responders versus non-responders, supported by altered ex vivo IFNγ plasma levels. Further analysis of HBV-specific CD8+ T cell responses in 22 HLA-A*02-positive patients indicated distinct response patterns between core18 and pol455 stimulation, with pol455-specific CD8+ T cells showing increased susceptibility to DAC/αPD-L1, surpassing the αPD-L1 monotherapy response. Conclusions: The combination of DAC/αPD-L1 shows promise in improving HBV-specific T cell responses in vitro, highlighting the potential of remodeling exhaustion-associated epigenetic signatures to enhance HBV-specific T cell restoration and suggesting a novel immunotherapeutic avenue for chronic HBV infection.
- 19 December 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 82 (3) , 739-754
Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition
Background and Aims: Chronic HBV infection exhausts HBV-specific T cells, develops epigenetic imprints that impair immune responses, and limits the effectiveness of immune checkpoint inhibitor monotherapy, such as anti–programmed cell death ligand-1 antibody (αPD-L1). This study aimed to determine whether the DNA methyltransferase inhibitor decitabine (DAC) could reverse these epigenetic imprints and enhance immune checkpoint inhibitor efficacy in restoring HBV-specific T cell responses. Approach and Results: We investigated HBV-specific T cell responses by 10-day in vitro stimulation of peripheral blood mononuclear cells (PBMCs) from patients with chronic HBV infection. PBMCs were stimulated with HBV core-specific overlapping peptide pools and HLA-A*02–restricted peptides, core18 and pol455. The immunomodulatory effect of the DAC/αPD-L1 combination was assessed by flow cytometry, and our analysis included clinical characteristics, ex vivo DNA methylation of PBMCs, and IFNγ plasma levels. Treatment with DAC/αPD-L1 enhanced HBV-specific CD4+ T cell responses in a significant proportion of 53 patients, albeit with some variability. This effect was independent of the HBcrAg levels. Ex vivo DNA methylation revealed hypermethylation of key genes, such as IFNG among DAC-responders versus non-responders, supported by altered ex vivo IFNγ plasma levels. Further analysis of HBV-specific CD8+ T cell responses in 22 HLA-A*02-positive patients indicated distinct response patterns between core18 and pol455 stimulation, with pol455-specific CD8+ T cells showing increased susceptibility to DAC/αPD-L1, surpassing the αPD-L1 monotherapy response. Conclusions: The combination of DAC/αPD-L1 shows promise in improving HBV-specific T cell responses in vitro, highlighting the potential of remodeling exhaustion-associated epigenetic signatures to enhance HBV-specific T cell restoration and suggesting a novel immunotherapeutic avenue for chronic HBV infection.
- Open Access
- 31 August 2023
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 12 (2) , 2251598
Enhanced monitoring and detection of recent genotype 3 hepatitis E virus infection through urine antigen testing
Hepatitis E virus (HEV) is the leading cause of acute viral hepatitis. Numerous studies have investigated the dynamics of HEV infection markers, but the most suitable marker for diagnosing ongoing or recent HEV infection remains to be determined. Recent evidence suggests that serum antigen testing is superior to serum IgM and RNA quantification. Moreover, it has been found that infected individuals excrete HEV antigen in significant quantities through urine. To address this question, we conducted a longitudinal analysis involving 16 patients with acute or chronic HEV infection in an area where genotype 3 HEV is prevalent. Our findings indicate that the diagnostic and monitoring capabilities of antigen testing for HEV infection can be further enhanced by measuring it in urine. Additionally, we were able to demonstrate that this enhancement is likely due to the presence of HEV-reactive IgG in blood plasma, which hampers efficient detection of HEV antigen through sandwich ELISA. In conclusion, urine-based antigen testing appears to be superior to measuring anti-HEV antibodies or viral RNA for diagnosing suspected HEV infection and monitoring ongoing infections.
- 31 August 2023
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 12 (2) , 2251598
Open AccessEnhanced monitoring and detection of recent genotype 3 hepatitis E virus infection through urine antigen testing
Hepatitis E virus (HEV) is the leading cause of acute viral hepatitis. Numerous studies have investigated the dynamics of HEV infection markers, but the most suitable marker for diagnosing ongoing or recent HEV infection remains to be determined. Recent evidence suggests that serum antigen testing is superior to serum IgM and RNA quantification. Moreover, it has been found that infected individuals excrete HEV antigen in significant quantities through urine. To address this question, we conducted a longitudinal analysis involving 16 patients with acute or chronic HEV infection in an area where genotype 3 HEV is prevalent. Our findings indicate that the diagnostic and monitoring capabilities of antigen testing for HEV infection can be further enhanced by measuring it in urine. Additionally, we were able to demonstrate that this enhancement is likely due to the presence of HEV-reactive IgG in blood plasma, which hampers efficient detection of HEV antigen through sandwich ELISA. In conclusion, urine-based antigen testing appears to be superior to measuring anti-HEV antibodies or viral RNA for diagnosing suspected HEV infection and monitoring ongoing infections.
- 18 July 2017
- Published by Wiley in Liver International
- Vol. 38 (2) , 266-277
Hepatitis E virus ORF 1 induces proliferative and functional T‐cell responses in patients with ongoing and resolved hepatitis E
Background and Aims: Hepatitis E virus (HEV) is a major cause of acute viral hepatitis with >3 million symptomatic cases per year accounting for 70 000 HEV‐related deaths. HEV‐specific T‐cell responses have been investigated against structural proteins expressed by open reading frames (ORF) 2 and 3. T‐cell responses against non‐structural HEV proteins encoded by ORF1 are hardly studied. The aim of this study was to determine HEV ORF1‐specific T‐cell responses in comparison to ORF2/3 in patients exposed to HEV.Methods: HEV‐specific CD4+ and CD8+ T‐cell responses against HEV genotype 3 were investigated in patients with acute and chronic hepatitis E as well as in HEV seropositive and seronegative individuals. HEV‐specific T‐cell responses were determined by proliferation and intracellular cytokine assay upon stimulation of PBMCs with HEV‐specific overlapping peptide pools spanning the entire HEV genome. HEV‐antigen was measured using an anti‐HEV antigen‐specific ELISA.Results: Broad HEV ORF1‐specific T‐cell responses were detected in patients with acute, resolved and chronic hepatitis E without distinct dominant regions. The magnitude and frequency in recognition of ORF1‐specific T‐cell responses were similar compared to responses against HEV ORF2/3. Longitudinal studies of HEV‐specific T‐cell responses displayed similar behaviour against structural and non‐structural proteins. HEV‐antigen levels were inversely correlated with HEV‐specific T‐cell responses.Conclusions: HEV‐specific T‐cell responses are detectable against the entire HEV genome including the non‐structural proteins. HEV‐specific T‐cell responses are associated with control of HEV infection. These findings have implications for the design of HEV vaccines.
- 18 July 2017
- Published by Wiley in Liver International
- Vol. 38 (2) , 266-277
Hepatitis E virus ORF 1 induces proliferative and functional T‐cell responses in patients with ongoing and resolved hepatitis E
Background and Aims: Hepatitis E virus (HEV) is a major cause of acute viral hepatitis with >3 million symptomatic cases per year accounting for 70 000 HEV‐related deaths. HEV‐specific T‐cell responses have been investigated against structural proteins expressed by open reading frames (ORF) 2 and 3. T‐cell responses against non‐structural HEV proteins encoded by ORF1 are hardly studied. The aim of this study was to determine HEV ORF1‐specific T‐cell responses in comparison to ORF2/3 in patients exposed to HEV.Methods: HEV‐specific CD4+ and CD8+ T‐cell responses against HEV genotype 3 were investigated in patients with acute and chronic hepatitis E as well as in HEV seropositive and seronegative individuals. HEV‐specific T‐cell responses were determined by proliferation and intracellular cytokine assay upon stimulation of PBMCs with HEV‐specific overlapping peptide pools spanning the entire HEV genome. HEV‐antigen was measured using an anti‐HEV antigen‐specific ELISA.Results: Broad HEV ORF1‐specific T‐cell responses were detected in patients with acute, resolved and chronic hepatitis E without distinct dominant regions. The magnitude and frequency in recognition of ORF1‐specific T‐cell responses were similar compared to responses against HEV ORF2/3. Longitudinal studies of HEV‐specific T‐cell responses displayed similar behaviour against structural and non‐structural proteins. HEV‐antigen levels were inversely correlated with HEV‐specific T‐cell responses.Conclusions: HEV‐specific T‐cell responses are detectable against the entire HEV genome including the non‐structural proteins. HEV‐specific T‐cell responses are associated with control of HEV infection. These findings have implications for the design of HEV vaccines.
- 1 April 2015
- Published by Elsevier in Journal of Hepatology
- Vol. 62, S524-S525
P0559 : Evaluation of large, middle and small hepatitis B surface (HBS) proteins in HBeAg positive patients
- 1 April 2015
- Published by Elsevier in Journal of Hepatology
- Vol. 62, S524-S525
P0559 : Evaluation of large, middle and small hepatitis B surface (HBS) proteins in HBeAg positive patients